|
|
 |
|
Viewing report
|
|
|
|
Anxiety Disorders - Global Strategic Business Report
Global Industry Analysts, Inc, April 2011, Pages: 619
This report analyzes the worldwide markets for Anxiety Disorders in US$ Million. The report provides separate comprehensive analytics for the US, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2017. Also, a six-year historic analysis is provided for these markets. The report profiles 63 companies including many key and niche players such as AstraZeneca Plc, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Forest Laboratories, Inc., GlaxoSmithKline Plc, H. Lundbeck A/S, Mylan, Inc., Neurocrine Biosciences, Inc., Pfizer, Inc., Ratiopharm, Sanofi-Aventis, Valeant Pharmaceuticals International, and Watson Laboratories, Inc. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.
Please note: Reports are sold as single-site single-user licenses. The delivery time for electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks.
For information on site licence pricing please click on Enquire before buying
Please note: Reports are sold as single-site single-user licenses. The delivery time for hard copies is between 3-5 business days, as each hard copy is custom printed for the organization ordering it. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks.
For information on site licence pricing please click on Enquire before buying
|
|
|
|
